# US 2001/0024797 A1 · Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024797 A1
- Document ID: US20010024797A1
- Status: Published application
- Kind: A1
- Application number: 09/823,418
- Filed: 2001-03-29
- Published: 2001-09-27
- Earliest claimed: 1998-03-10
- Assignees: The Regents of the University of California
- Inventors: Thomas Innerarity; Jan Boren
- Web page: https://patentgrep.com/patent/US20010024797A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2800/323: Arteriosclerosis, Stenosis
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S 977/914: Protein engineering
- Y10T 436/104165: Lipid, cholesterol, or triglyceride standard or control
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.

## Claims

### Claim 1

A method for identifying compounds that affect LDL-proteoglycan binding, comprising the steps of:
(a) incubating a mixture comprising (i) proteoglycan, (ii) LDL, and (iii) a candidate compound, under conditions wherein LDL binds to proteoglycan to form an LDL-proteoglycan complex in the absence of said candidate compound;
(b) determining any difference between the amount of LDL-proteoglycan complex present in:
(i) the mixture prepared in step (a), and
(ii) a assay mixture comprising said proteoglycan and said LDL in the absence of said candidate compound.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising the step of
(c) correlating any difference determined in step (b) with said candidate compound's ability to affect LDL-proteoglycan binding.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, wherein the LDL of step (a) is attached to a solid support.

### Claim 4 (depends on 1, 2)

The method according to claim 1 or 2, wherein the proteoglycan of step (a) is attached to a solid support.

### Claim 5 (depends on 1, 2, 4)

The method according to claim 1, 2 or 4, wherein the LDL of step (a) is labeled.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the proteoglycan of step (a) is labeled.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the label is biotin.

### Claim 8 (depends on 7)

The method according to claim 7, further comprising the steps of:
contacting the solid support after the preparation of the assay mixture of step (a) with streptavidin peroxidase under conditions wherein biotin binds to streptavidin to form a biotin-avidin complex;
detecting any enzyme activity of the peroxidase bound to the solid support.

### Claim 9 (depends on 1, 2)

The method according to claim 1 or 2, wherein the proteoglycan of step (a) is labeled.

### Claim 10 (depends on 2)

A method for identifying compounds which affect LDL-proteoglycan binding, which do not substantially affect LDL receptor binding, according to claims 2, further comprising the steps of:
(d) incubating a mixture comprising (i) LDL receptor, (ii) LDL, and (iii) a candidate compound that affects LDL-proteoglycan binding identified in step (c), under conditions wherein LDL binds to LDL receptor to form an LDL-LDL receptor complex in the absence of said inhibitor of LDL-proteoglycan binding;
(e) determining any difference between the amount of LDL-LDL receptor complex present in:
(i) the mixture prepared in step (d), and
(ii) a control mixture comprising said LDL receptor and said LDL in the absence of said inhibitor of LDL-proteoglycan binding.

### Claim 11 (depends on 11)

The method according to claim 11, further comprising the step of:
(f) correlating any difference determined in step (e) with said candidate compound's ability to affect LDL-LDL receptor binding activity.

### Claim 12 (depends on 1, 2)

The compounds that affect LDL-proteoglycan binding identified by the method according to claim 1 or 2.

### Claim 13 (depends on 10, 11)

The compounds which affect LDL-proteoglycan binding, which do not substantially affect LDL receptor binding identified by the method according to claim 10 or 11.

### Claim 14

A apo-B100 protein comprising a proteoglycan−receptor+ mutation in Site B.

### Claim 15 (depends on 14)

The apo-B100 protein according to claim 14, which is purified.

### Claim 16 (depends on 14)

The apo-B100 protein according to claim 14, which is synthesized by recombinant DNA expression or chemical synthesis.

### Claim 17 (depends on 14)

The apo-B100 protein according to claim 14, wherein the amino acid sequence from position 3358 to 3359 is selected from the group consisting of:
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Glu3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Asp3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Ala3363-Arg3364-Gly3365-Leu3366-Lys3367
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Thr3363-Arg3364-Gly3365-Leu3366-Lys3367
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Ser3363-Arg3364-Gly3365-Leu3366-Lys3367
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Gln3363-Arg3364-Gly3365-Leu3366-Lys3367
Thr3358-Arg3359-Leu3360-Thr3361-Glu3362-Lys3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Asp3362-Lys3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Lys3363-Glu3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Lys3363-Asp3364-Gly3365-Leu3366-Lys3367,
Thr3358-Glu3359-Leu3360-Thr3361-Arg3362-Lys3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-ASP3359-Leu3360-Thr3361-Arg3362-Lys3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362. . . Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361. . . Lys3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Lys3363. . . Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Glu-Lys3363-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Lys3363-Glu-Arg3364-Gly3365-Leu3366-Lys3367,
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Asp-Lys3363-Arg3364-Gly3365-Leu3366-Lys3367, and
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Lys3363-Asp-Arg3364-Gly3365-Leu3366-Lys3367.

### Claim 18 (depends on 14)

The apo-B100 protein according to claim 14, wherein said mutation in Site B is the K3363E mutation, and the amino acid sequence from position 3358 to 3359 is:
Thr3358-Arg3359-Leu3360-Thr3361-Arg3362-Glu3363-Arg3364-Gly3365-Leu3366-Lys3367.

### Claim 19 (depends on 14, 15, 16, 17, 18)

A polypeptide comprising the amino acid sequence of Site B in the apo-B100 protein according to any one of claims 14 to 18, wherein said Site B is flanked on at least one side by a contiguous sequence of at least 10 amino acids which is directly adjacent to Site B in the wild-type human apo-B100 sequence.

### Claim 20 (depends on 14, 15, 16, 17, 18)

An LDL particle comprising an apo-B100 protein according to any one of claims 14 to 18.

### Claim 21 (depends on 19)

An LDL particle comprising a polypeptide according to claim 19.

### Claim 22 (depends on 14, 15, 16, 17, 18)

An antibody composition which binds to an antigenic determinant in an apo-B100 protein according to any one of claims 14 to 18, wherein said antigenic determinant is not present in the wild-type human apo-B100 protein.

### Claim 23 (depends on 14, 15, 16, 17, 18)

A polynucleotide encoding an apo-B100 protein according to any one of claims 14 to 18.

### Claim 24 (depends on 23)

The polynucleotide according to claim 23, wherein the polynucleotide is present in a 95-kb apo-B P1 plasmid p158.

### Claim 25 (depends on 24)

The polynucleotide according to claim 24, wherein said mutation in Site B is the K3363E mutation.

### Claim 26 (depends on 23, 24, 25)

A cell comprising polynucleotide according to any one of claims 23 to 25.

### Claim 27 (depends on 23, 24, 25)

A non-human animal comprising a polynucleotide according to any one of claims 23 to 25.

### Claim 28 (depends on 23, 24, 25)

A method for preventing or reducing the severity of atherosclerosis in a animal, comprising expressing a polynucleotide according to any one of claims 23 to 25.
